193 related articles for article (PubMed ID: 25471597)
1. B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis.
Brühl H; Cihak J; Talke Y; Rodriguez Gomez M; Hermann F; Goebel N; Renner K; Plachý J; Stangassinger M; Aschermann S; Nimmerjahn F; Mack M
Eur J Immunol; 2015 Mar; 45(3):705-15. PubMed ID: 25471597
[TBL] [Abstract][Full Text] [Related]
2. Rehabilitation or the death penalty: autoimmune B cells in the dock.
Dahal LN; Cragg MS
Eur J Immunol; 2015 Mar; 45(3):687-91. PubMed ID: 25639261
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
Veri MC; Burke S; Huang L; Li H; Gorlatov S; Tuaillon N; Rainey GJ; Ciccarone V; Zhang T; Shah K; Jin L; Ning L; Minor T; Moore PA; Koenig S; Johnson S; Bonvini E
Arthritis Rheum; 2010 Jul; 62(7):1933-43. PubMed ID: 20506263
[TBL] [Abstract][Full Text] [Related]
4. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity.
Yanaba K; Hamaguchi Y; Venturi GM; Steeber DA; St Clair EW; Tedder TF
J Immunol; 2007 Jul; 179(2):1369-80. PubMed ID: 17617630
[TBL] [Abstract][Full Text] [Related]
5. B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis.
Olalekan SA; Cao Y; Hamel KM; Finnegan A
Eur J Immunol; 2015 Apr; 45(4):988-98. PubMed ID: 25645456
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
[TBL] [Abstract][Full Text] [Related]
7. Anti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance.
Nguyen TG; Little CB; Yenson VM; Jackson CJ; McCracken SA; Warning J; Stevens V; Gallery EG; Morris JM
J Autoimmun; 2010 Aug; 35(1):86-97. PubMed ID: 20456921
[TBL] [Abstract][Full Text] [Related]
8. Etanercept attenuates collagen-induced arthritis by modulating the association between BAFFR expression and the production of splenic memory B cells.
Wang QT; Wu YJ; Huang B; Ma YK; Song SS; Zhang LL; Chen JY; Wu HX; Sun WY; Wei W
Pharmacol Res; 2013 Feb; 68(1):38-45. PubMed ID: 23178558
[TBL] [Abstract][Full Text] [Related]
9. Suppression of humoral immunity by monoclonal antibody to CD79b, an invariant component of antigen receptors on B lymphocytes.
Nakamura T; Koyama M; Koike Y; Miyazaki K; Yoneyema A; Higashihara M; Azuma M; Kurokawa K
Int J Hematol; 1996 Jul; 64(1):39-46. PubMed ID: 8757966
[TBL] [Abstract][Full Text] [Related]
10. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
11. Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity.
Seki N; Sudo Y; Yoshioka T; Sugihara S; Fujitsu T; Sakuma S; Ogawa T; Hamaoka T; Senoh H; Fujiwara H
J Immunol; 1988 Mar; 140(5):1477-84. PubMed ID: 3257978
[TBL] [Abstract][Full Text] [Related]
12. ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ Treg cells and induces sustained amelioration of collagen-induced arthritis.
Notley CA; McCann FE; Inglis JJ; Williams RO
Arthritis Rheum; 2010 Jan; 62(1):171-8. PubMed ID: 20039431
[TBL] [Abstract][Full Text] [Related]
13. Expanded CD23(+)/CD21(hi) B cells in inflamed lymph nodes are associated with the onset of inflammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy.
Li J; Kuzin I; Moshkani S; Proulx ST; Xing L; Skrombolas D; Dunn R; Sanz I; Schwarz EM; Bottaro A
J Immunol; 2010 Jun; 184(11):6142-50. PubMed ID: 20435928
[TBL] [Abstract][Full Text] [Related]
14. B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives.
Nakken B; Munthe LA; Konttinen YT; Sandberg AK; Szekanecz Z; Alex P; Szodoray P
Autoimmun Rev; 2011 Nov; 11(1):28-34. PubMed ID: 21777703
[TBL] [Abstract][Full Text] [Related]
15. B cells influence sex specificity of arthritis via myeloid suppressors and chemokines in humanized mice.
Behrens M; Luckey D; Luthra H; David C; Taneja V
Clin Immunol; 2017 May; 178():10-19. PubMed ID: 26057130
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
[TBL] [Abstract][Full Text] [Related]
18. Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells.
Nandakumar KS; Bäcklund J; Vestberg M; Holmdahl R
Arthritis Res Ther; 2004; 6(6):R544-50. PubMed ID: 15535832
[TBL] [Abstract][Full Text] [Related]
19. B-cell: a logical target for treatment of rheumatoid arthritis.
Youinou P; Jamin C; Saraux A
Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
[TBL] [Abstract][Full Text] [Related]
20. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
